IP Verse

Intas Pharmaceuticals, Ltd. et al. vs Atossa Therapeutics, Inc.

The detailed information for PTAB case with proceeding number PGR2025-00043 filed by Intas Pharmaceuticals, Ltd. et al. against Atossa Therapeutics, Inc. on Apr 3, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: PGR2025-00043
Filing Date: Apr 3, 2025
Petitioner: Intas Pharmaceuticals, Ltd. et al.
Respondent: Atossa Therapeutics, Inc.
Status: Pending
Respondent Application Number: 18128536
Respondent Tech Center: 1600
Respondent Patent Number: 12071391

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
EX2001 - ATOSSA THERAPEUTICS, INC. QUARTERLY REPORT FORM 10-Q for the Quarterly Period Ended March 31, 2025	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2002 - Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 (April 29, 2025)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2003 - Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications (March 11, 2025)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2004 - Financials – Intas Pharmaceuticals Ltd.	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2005 - Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen (March 8, 2022)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2006 - Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients, NCT06608641 (Last Updated March 17, 2025)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2008 - Atossa Covenant Not to Sue	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2009 - Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density (Dec. 11, 2024)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2010 - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update (May 13, 2025)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2012 - Breast Center Year in Review, An Unmet Need in HR-Positive Endocrine-Resistant Breast Cancer	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2013 - ATOSSA THERAPEUTICS, INC. ANNUAL REPORT FORM 10-K for the Fiscal Year Ended December 31, 2024	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2015 - Intas Requirements For Resolving Disputes With Atossa (FILED UNDER SEAL)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2016 - Default Protective Order	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2017 - Intas Pharmaceuticals, Limited v. Atossa Therapeutics, Inc., IPR2025-00799, Pap.2 (Apr. 3, 2025)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2018 - Intas Pharmaceuticals, Limited v. Atossa Therapeutics, Inc., PGR2023-00043, Pap.1 (Aug. 18, 2023)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2019 - Rishab Gupta & Swarndeep Singh, Endoxifen Approval for Bipolar in India, A Premature or a Pragmatic Decision?, 43(1) J. CLINICAL PSYCHOPHARMACOLOGY 3 (2023)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2020 - Zonalta, Why Zonalta?	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2021 - Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (August 28, 2024)	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2022 - Declaration of Megan Raymond	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2007 - Declaration of Sayem Osman	Jul 7, 2025	EXHIBIT	PATENT OWNER
EX2014 - U.S. Patent No. 11,572,334	Jul 7, 2025	EXHIBIT	PATENT OWNER
Patent Owner's Motion to Seal	Jul 7, 2025	PAPER	PATENT OWNER
Patent Owner's Discretionary Denial Request [FILED UNDER SEAL]	Jul 7, 2025	PAPER	PATENT OWNER
Patent Owner's Discretionary Denial Request [REDACTED]	Jul 7, 2025	PAPER	PATENT OWNER
Notice: Notice filing date accorded	May 5, 2025	PAPER	BOARD
Power of Attorney and Designation of Lead Back-Up Counsel	Apr 17, 2025	PAPER	PATENT OWNER
Patent Owner's Mandatory Notices	Apr 17, 2025	PAPER	PATENT OWNER
USPN 12,071,391	Apr 3, 2025	EXHIBIT	PETITIONER
File history of USPN 12,071,391	Apr 3, 2025	EXHIBIT	PETITIONER
9,333,190 (Ahmad)	Apr 3, 2025	EXHIBIT	PETITIONER
WO2017/70651 (Liu)	Apr 3, 2025	EXHIBIT	PETITIONER
Excerpt of Handbook of Pharmaceutical Salts	Apr 3, 2025	EXHIBIT	PETITIONER
Benameur	Apr 3, 2025	EXHIBIT	PETITIONER
de Villiers	Apr 3, 2025	EXHIBIT	PETITIONER
Stegemann	Apr 3, 2025	EXHIBIT	PETITIONER
Excerpts of Handbook of Pharmaceutical Excipients	Apr 3, 2025	EXHIBIT	PETITIONER
Cole	Apr 3, 2025	EXHIBIT	PETITIONER
Ahmad (2010)	Apr 3, 2025	EXHIBIT	PETITIONER
Ahmad (2012)	Apr 3, 2025	EXHIBIT	PETITIONER
Fauq (2010)	Apr 3, 2025	EXHIBIT	PETITIONER
Milroy	Apr 3, 2025	EXHIBIT	PETITIONER
Krahn	Apr 3, 2025	EXHIBIT	PETITIONER
A Focus on Crystallography	Apr 3, 2025	EXHIBIT	PETITIONER
Fan	Apr 3, 2025	EXHIBIT	PETITIONER
Urso	Apr 3, 2025	EXHIBIT	PETITIONER
Endoxifen	Apr 3, 2025	EXHIBIT	PETITIONER
Ansel - capsules	Apr 3, 2025	EXHIBIT	PETITIONER
Beasley	Apr 3, 2025	EXHIBIT	PETITIONER
WO2011/107855 (Gandhi)	Apr 3, 2025	EXHIBIT	PETITIONER
11,572,334	Apr 3, 2025	EXHIBIT	PETITIONER
Supporting Information to Milroy	Apr 3, 2025	EXHIBIT	PETITIONER
Ali	Apr 3, 2025	EXHIBIT	PETITIONER
Supporting Information to Fauq	Apr 3, 2025	EXHIBIT	PETITIONER
Elkins	Apr 3, 2025	EXHIBIT	PETITIONER
Reid	Apr 3, 2025	EXHIBIT	PETITIONER
Shargel	Apr 3, 2025	EXHIBIT	PETITIONER
Ansel	Apr 3, 2025	EXHIBIT	PETITIONER
Wieckhusen	Apr 3, 2025	EXHIBIT	PETITIONER
Richardson	Apr 3, 2025	EXHIBIT	PETITIONER
Expert Declaration of Jason McConville, Ph.D.	Apr 3, 2025	EXHIBIT	PETITIONER
Expert Declaration of Ron Bihovsky, Ph.D.	Apr 3, 2025	EXHIBIT	PETITIONER
Notice: Power of Attorney	Apr 3, 2025	PAPER	PETITIONER
Petition: as filed	Apr 3, 2025	PAPER	PETITIONER